Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Profit After Tax (2020 - 2025)

Bolt Biotherapeutics' Profit After Tax history spans 6 years, with the latest figure at -$7.1 million for Q3 2025.

  • For Q3 2025, Profit After Tax rose 52.93% year-over-year to -$7.1 million; the TTM value through Sep 2025 reached -$42.7 million, up 34.42%, while the annual FY2024 figure was -$63.1 million, 8.79% up from the prior year.
  • Profit After Tax for Q3 2025 was -$7.1 million at Bolt Biotherapeutics, up from -$8.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$7.1 million in Q3 2025 and bottomed at -$27.2 million in Q4 2021.
  • The 5-year median for Profit After Tax is -$18.1 million (2023), against an average of -$18.2 million.
  • The largest annual shift saw Profit After Tax plummeted 183.26% in 2021 before it skyrocketed 59.61% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$27.2 million in 2021, then grew by 26.37% to -$20.0 million in 2022, then rose by 10.47% to -$17.9 million in 2023, then rose by 10.99% to -$15.9 million in 2024, then surged by 55.17% to -$7.1 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Profit After Tax are -$7.1 million (Q3 2025), -$8.6 million (Q2 2025), and -$11.0 million (Q1 2025).